Cytomos Overview
Latest Deal Type
Early Stage VC
Latest Deal Amount
$2.13M
Cytomos General Information
Description
Developer of a medical diagnostics technology designed to assist in label-free cell analysis for biomedical research. The company's patented cell analysis technology ensures that every cell is analysed providing granular information on individual cells and the whole sample population, facilitates automated and quantitative sample assessment, phenotypic drug discovery and stem cell therapy, enabling medical researchers to find functional end points that conventional assays cannot reach and generate high-content fingerprints to select the right dose for the right patients, thereby making cell-based diagnostics quicker and simpler.
Want to dig into this profile?
We’ll help you find what you need
Learn more
Cytomos Valuation & Funding
| Deal Type |
Date |
Amount |
Raised to Date |
Post-Val |
Status |
Stage |
| 3. Early Stage VC |
23-Apr-2018 |
$2.13M |
00.000 |
00.000 |
Completed |
Startup |
| 2. Early Stage VC |
16-Feb-2016 |
00000 |
00000 |
00.000 |
Completed |
Startup |
| 1. Angel (individual) |
15-Dec-2014 |
$157K |
$157K |
00000 |
Completed |
Startup |
Cytomos Cap Table
To view Cytomos‘s complete cap table, request access >>
| Stock |
# of Shares
Authorized |
Par Value |
Dividend Rate (%) |
Original
Issue Price |
Liquidation |
Liquidation
Pref. Multiple |
Conversion Price |
% Owned |
| Ordinary |
000,000 |
00.000000 |
|
000.00 |
000.00 |
00 |
000.00 |
00.000 |
| Ordinary |
000,000 |
00.000000 |
|
00.00 |
00.00 |
00 |
00.00 |
00.000 |
| Ordinary |
19,800 |
$0.000014 |
|
$7.14 |
$7.14 |
1x |
$7.14 |
4.78% |
Cytomos Executive Team (1)
| Name |
Title |
Board Seat |
Contact Info |
| Keith Muir Ph.D |
Founder & Chief Executive Officer |
|
|
Cytomos Board Members (3)
| Name |
Representing |
Role |
Since |
| Alister Minty |
Self |
Chairman |
000 0000
|
| Gino Miele Ph.D |
Self |
Board Member |
000 0000
|
| Margaret Temple |
Self |
Board Member |
000 0000
|